{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:27:17Z","timestamp":1791379637303,"version":"4.3.3"},"reference-count":104,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Introduction\nSchizophrenia is a severe psychotic disorder that is diagnosed by the presence of hallucinations or delusions along with disorganized speech, disorganized thought, or negative symptoms that are present for at least six months. Roughly 1 in 10,000 people a year are diagnosed with this psychiatric disorder. It is a chronic disorder requiring a lifetime of treatment of which antipsychotics have been the mainstay of this treatment. First-generation antipsychotics have dystonia, parkinsonism, and development of Tardive Dyskinesia as major side effects, and they are also nonspecific in terms of their actions. Second Generation antipsychotics target more specific dopamine and sometimes serotonin receptors with less dystonic side effects; however, there are additional concerns for the development of metabolic syndrome. This review aims to look at new medication on the market, lumateperone, for the treatment of Schizophrenia.\nRecent studies\nIn one four week study with 60mg and 120mg of Lumateperone compared, 4mg of Risperdal, and a placebo found that Lumateperone significantly decreased the total Positive and Negative Syndrome Scale (PANSS) from baseline. Safety analysis of this study also found that Lumateperone was not associated with EPS or significant weight gain. Another study found that 42mg of Lumateperone significantly decreased PANSS score over placebo and 28mg of Lumateperone with associated TEAEs of somnolence, sedation, fatigue, and constipation. In an open-label safety, patients were switched from their current antipsychotic to Lumateperone and then switched back to their previous treatment after six weeks. PATIENTS were found to have statistically significant improvements in metabolic parameters, weight, and endocrine parameters, which were all lost when they were switched back to their previous treatment and their schizophrenic symptoms at pre-trial levels or improved them while on Lumateperone. In a continuation of the previous study over 12 months, 4 TEAEs occurred in 5% or more of the participants: diarrhea, dry mouth, weight decrease, and headache. Prolactin, metabolic labs, BMI, and weight all decreased as compared to the standard of care. Pooled studies revealed EPS related TEAEs were less frequent in patients receiving 42 mg lumateperone over Risperdal. Another pooled study looked at the safety profile; they found patients treated with lumateperone, two TEAEs occurred at twice the placebo rate and at a rate of 5% or more: dry mouth (5% vs. 2.2%) and sedation (24.1% vs. 10.0%) though TEAE discontinuation rates were lower than with Risperdal.\nSummary\nTaken together, data from these trials suggest that lumateperone can effectively treat positive symptoms, negative symptoms, and cognitive dysfunction in schizophrenia. Lumateperone entrance to the market introduces an innovative way to treat schizophrenia featuring both a novel mechanism of action and a markedly reduced side effect profile. Further research is needed to determine the efficacy of Lumateperone in treating bipolar disorder in addition to schizophrenia.<\/jats:p>","DOI":"10.64719\/pb.4372","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"32-59","source":"Crossref","is-referenced-by-count":11,"title":["Lumateperone for the Treatment of Schizophrenia"],"prefix":"10.64719","volume":"50","author":[{"given":"Amber","family":"Edinoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"deBoisblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Olivia","family":"Feltner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Norder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesela","family":"Tzoneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S et al. Definition and description of schizophrenia in the DSM-5. 2013;150:3\u201310. Vol. Schizophrenia Research. Elsevier.","DOI":"10.1016\/j.schres.2013.05.028"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. 2006;39:161\u201370. [Internet] Pharmacopsychiatry. \u00a9 Georg Thieme Verlag K.G. Stuttgart \u00b7 New York. [cited 2020 Aug 2] Available from: http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-2006-949513.","DOI":"10.1055\/s-2006-949513"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Braff DL, Ryan J, Rissling AJ, Carpenter WT. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull. 2013;39(4):751\u2013753.","DOI":"10.1093\/schbul\/sbt068"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mcgrath J, Saha S, Chant D, Welham J. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. [cited 2020 Aug 2] Available from: https:\/\/academic.oup.com\/epirev\/article-abstract\/30\/1\/67\/621138.","DOI":"10.1093\/epirev\/mxn001"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: Evidence from meta-analysis. Arch Gen Psychiatry. 2003 Jun 1;60(6):565\u2013571. [Internet] [cited 2020 Aug 2] Available from: https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/207514.","DOI":"10.1001\/archpsyc.60.6.565"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet Psychiatry. 2017 Apr 1;4(4):295\u2013301. [Internet] [cited 2020 Aug 2] Available from: http:\/\/www.thelancet.com\/article\/S2215036617300780\/fulltext.","DOI":"10.1016\/S2215-0366(17)30078-0"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc. 2002 Dec 4;288(21):2709\u20132716. [Internet] [cited 2020 Aug 2] Available from: https:\/\/jamanetwork.com\/","DOI":"10.1001\/jama.288.21.2709"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Siris SG. Suicide and schizophrenia. 2001;15:127\u2013135. [Internet] Journal of Psychopharmacology. SAGE Publications Ltd. [cited 2020 Aug 2] Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/026988110101500209.","DOI":"10.1177\/026988110101500209"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sher L, Kahn RS. Suicide in schizophrenia: An educational overview. 2019;55 [Internet] Medicina (Lithuania). MDPI AG. [cited 2020 Aug 2]. Available from: \/pmc\/articles\/PMC6681260\/?report=abstract.","DOI":"10.3390\/medicina55070361"},{"key":"ref10","unstructured":"Janoutov\u00e1 J, Jan\u00e1\u010dkov\u00e1 P, \u0160er\u00fd O, Zeman T, Ambroz P, Kovalov\u00e1 M et al. Epidemiology and risk factors of Schizophrenia. 2016;37:1\u20138. [Internet] Neuroendocrinology Letters. Maghira and Maas Publications. [cited 2020 Aug 2] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26994378\/"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"H\u00e4fner H, an der Heiden W. Epidemiology of schizophrenia. 1997 Mar 30;42(2):139\u2013151. Can J Psychiatry [Internet] [cited 2020 Aug 2] Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9067063.","DOI":"10.1177\/070674379704200204"},{"key":"ref12","unstructured":"Mueser KT, Jeste DV. Guilford Press; 2008. Clinical Handbook of Schizophrenia."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Laursen TM, Nordentoft M, Mortensen PB. Excess Early Mortality in Schizophrenia. Annu Rev Clin Psychol. 2014 Mar 28;10(1):425\u2013448. [Internet] [cited 2020 Aug 2] Available from: http:\/\/www.annualreviews.org\/doi\/10.1146\/annurev-clinpsy-032813-153657.","DOI":"10.1146\/annurev-clinpsy-032813-153657"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG et al. Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195\u20131203.","DOI":"10.1093\/schbul\/sby058"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Thomas P, Mathur P, Gottesman II, Nagpal R, Nimgaonkar VL, Deshpande SN. Correlates of hallucinations in schizophrenia: A cross-cultural evaluation. Schizophr Res. 2007 May;92(1\u20133):41\u201349. [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC5443754\/?report=abstract.","DOI":"10.1016\/j.schres.2007.01.017"},{"key":"ref16","unstructured":"Harvey PD, Khan A, Keefe RSE. Using the positive and negative syndrome scale (PANSS) to define different domains of negative symptoms: Prediction of everyday functioning by impairments in emotional expression and emotional experience. Innov Clin Neurosci. 2017 Nov 1;14(11\u201312):18\u201322. [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC5788247\/?report=abstract."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology. 1998 Jul;12(3):426\u2013445. [Internet] [cited 2020 Aug 2] Available from: \/record\/1998-04145-008.","DOI":"10.1037\/0894-4105.12.3.426"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426\u2013445.","DOI":"10.1037\/0894-4105.12.3.426"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006 Dec;2(4):531\u2013536.","DOI":"10.2147\/nedt.2006.2.4.531"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ragland JD, Ranganath C, Harms MP, Barch DM, Gold JM, Layher E et al. Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: A functional magnetic resonance imaging study of the relational and item-specific encoding task. In: JAMA Psychiatry. 2015:909\u2013916. [Internet]. American Medical Association. [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC4558363\/?report=abstract.","DOI":"10.1001\/jamapsychiatry.2015.0276"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sabhesan S, Parthasarathy S. Executive functions in schizophrenia. Indian J Psychiatry. 2005;47(1):21. [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC2918311\/?report=abstract.","DOI":"10.4103\/0019-5545.46069"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Psychiatric Association. 1996;153:321\u2013330. [Internet] American Journal of Psychiatry. [cited 2020 Aug 2] Available from: https:\/\/ajp.psychiatryonline.org\/doi\/abs\/10.1176\/ajp.153.3.321.","DOI":"10.1176\/ajp.153.3.321"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: A systematic review and meta-analysis. 2019;19:370. [Internet] BMC Psychiatry. BioMed Central Ltd. [cited 2020 Aug 2] Available from: https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2361-7.","DOI":"10.1186\/s12888-019-2361-7"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Stilo SA, Murray RM. Non-Genetic Factors in Schizophrenia. 2019;21 [Internet] Current Psychiatry Reports. Current Medicine Group LLC 1. [cited 2020 Jul 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31522306\/","DOI":"10.1007\/s11920-019-1091-3"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: Historical and meta-analytic review. 2002;159:1080\u20131092. [Internet] American Journal of Psychiatry. American Psychiatric Publishing. [cited 2020 Aug 2] Available from: https:\/\/ajp.psychiatryonline.org\/doi\/abs\/10.1176\/appi.ajp.159.7.1080.","DOI":"10.1176\/appi.ajp.159.7.1080"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull. 2006;32(1):3\u20138.","DOI":"10.1093\/schbul\/sbj028"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Whitfield CL, Dube SR, Felitti VJ, Anda RF. Adverse childhood experiences and hallucinations. Child Abus Negl. 2005 Jul 1;29(7):797\u2013810.","DOI":"10.1016\/j.chiabu.2005.01.004"},{"key":"ref28","unstructured":"van de Leemput J, Hess JL, Glatt SJ, Tsuang MT. Genetics of Schizophrenia: Historical Insights and Prevailing Evidence. 2016;96:99\u2013141. Adv Genet [Internet] [cited 2020 Jul 26] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27968732\/"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421\u20137. [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC4112379\/?report=abstract.","DOI":"10.1038\/nature13595"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysisof imaging studies. 2012 Aug;69(8):776\u2013786. Arch Gen Psychiatry [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC3730746\/?report=abstract.","DOI":"10.1001\/archgenpsychiatry.2012.169"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell P, Grace AA. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull. 1998;24(2):267\u2013283.","DOI":"10.1093\/oxfordjournals.schbul.a033325"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: Old fashioned, but still in vogue. 2014;5 [Internet] Frontiers in Psychiatry. Frontiers Media S.A. [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC4032934\/?report=abstract.","DOI":"10.3389\/fpsyt.2014.00047"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Laruelle M, Abi-Dargham A. SAGE Publications Ltd; 1999. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies; pp. 358\u201371. In: Journal of Psychopharmacology [Internet] [cited 2020 Aug 2] Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/026988119901300405.","DOI":"10.1177\/026988119901300405"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Patel NH, Vyas NS, Puri BK, Nijran KS, Al-Nahhas A. Positron emission tomography in schizophrenia: A new perspective. J Nucl Med. 2010 Apr 1;51(4):511\u2013520. [Internet] [cited 2020 Aug 2] Available from: http:\/\/jnm.snmjournals.org\/content\/51\/4\/511.full.","DOI":"10.2967\/jnumed.109.066076"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Lee G, Zhou Y. NMDAR Hypofunction Animal Models of Schizophrenia. 2019;12:185. [Internet] Frontiers in Molecular Neuroscience. Frontiers Media S.A. [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC6685005\/?report=abstract.","DOI":"10.3389\/fnmol.2019.00185"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. 2017;18 [Internet] International Journal of Molecular Sciences. MDPI AG. [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC5578079\/?report=abstract.","DOI":"10.3390\/ijms18081689"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. 2018;50:65\u201373. [Internet] Drug Metabolism Reviews. Taylor and Francis Ltd. [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC6419500\/?report=abstract.","DOI":"10.1080\/03602532.2018.1428343"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Howell LL, Cunningham KA. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. 2015;67:176\u2013197. [Internet] Pharmacological reviews. American Society for Pharmacology and Experimental Therapeutics. [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC4279075\/?report=abstract.","DOI":"10.1124\/pr.114.009514"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"St\u0119pnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. 2018;23 [Internet] Molecules. MDPI AG. [cited 2020 Jul 28]. Available from: \/pmc\/articles\/PMC6222385\/?report=abstract.","DOI":"10.3390\/molecules23082087"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical Dopamine D2D3 receptors are a common site of action for antipsychotic drugs-an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 2009;35(4):789\u2013797.","DOI":"10.1093\/schbul\/sbn009"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"MahapatraJ AC. Cochrane Library Cochrane Database of Systematic Reviews Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (Review) Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (Review) 2014","DOI":"10.1002\/14651858.CD001470.pub2"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 1999;1","DOI":"10.1002\/14651858.CD001361"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF et al. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. 2010 Feb 1;167(2):181\u2013189. Am J Psychiatry [Internet] [cited 2020 Aug 4] Available from: https:\/\/ajp.psychiatryonline.org\/doi\/abs\/10.1176\/appi.ajp.2009.07081221.","DOI":"10.1176\/appi.ajp.2009.07081221"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. 2017 Jul 1;74(7):686\u2013693. JAMA Psychiatry [Internet] [cited 2020 Jul 28] Available from: https:\/\/jamanetwork.com\/","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Waddell L, Taylor M. Vol. 195. Cambridge University Press: 2009. Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review; pp. s43\u201350. [Internet] British Journal of Psychiatry. [cited 2020 Aug 4] Available from: https:\/\/www.cambridge.org\/core.","DOI":"10.1192\/bjp.195.52.s43"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Emsley R, Kilian S, Phahladira L. How long should antipsychotic treatment be continued after a single episode of schizophrenia? 2016 May 1;29(3):224\u2013229. Curr Opin Psychiatry [Internet] [cited 2020 Aug 4] Available from: http:\/\/journals.lww.com\/00001504-201605000-00008.","DOI":"10.1097\/YCO.0000000000000249"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: A case for a common site of action of antipsychotics. Trends Pharmacol Sci. 1998 Apr;19(4):136\u2013140.","DOI":"10.1016\/S0165-6147(98)01186-9"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31\u201341. [Internet] [cited 2020 Aug 4] Available from: http:\/\/www.thelancet.com\/article\/S014067360861764X\/fulltext.","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST) Am J Psychiatry. 2009 Jun 1;166(6):675\u2013682. [Internet] [cited 2020 Aug 4] Available from: https:\/\/ajp.psychiatryonline.org\/doi\/abs\/10.1176\/appi.ajp.2008.08060806.","DOI":"10.1176\/appi.ajp.2008.08060806"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Bergemann N, Mundt C, Parzer P, Jannakos I, Nagl I, Salbach B et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res. 2005 Mar;73(2\u20133):357\u2013366.","DOI":"10.1016\/j.schres.2004.06.013"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003 Apr;28(SUPPL. 2):55\u201368.","DOI":"10.1016\/S0306-4530(02)00127-0"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Smith S, Wheeler MJ, Murray R, O\u2019Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22(2):109\u2013114.","DOI":"10.1097\/00004714-200204000-00002"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000 Mar 1;57(3):249\u2013258. [Internet] [cited 2020 Aug 4] Available from: https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/481579.","DOI":"10.1001\/archpsyc.57.3.249"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Correll CU, Leucht S, Kane JM. Lower Risk for Tardive Dyskinesia Associated with Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. American Psychiatric Publishing. 2004;161:414\u2013425. American Journal of Psychiatry.","DOI":"10.1176\/appi.ajp.161.3.414"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. J Clin Psychopharmacol. 2008;28(2):203\u2013209.","DOI":"10.1097\/JCP.0b013e318166c4d5"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. J Clin Psychiatry. 2017;78(3):e264\u2013278.","DOI":"10.4088\/JCP.16r10832"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330\u2013340.","DOI":"10.1002\/wps.20579"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013 Sep;382(9896):951\u2013962.","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. 2016 Nov 1;77(7):357\u2013367. Drug Dev Res [Internet] [cited 2020 Jul 28] Available from: http:\/\/doi.wiley.com\/10.1002\/ddr.21337.","DOI":"10.1002\/ddr.21337"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1061\u20131071.","DOI":"10.1176\/ajp.2007.164.7.1061"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: A large-scale, double-blind, randomized study. Psychopharmacology (Berl) 2003 Sep;169(3\u20134):404\u2013411.","DOI":"10.1007\/s00213-002-1342-5"},{"key":"ref62","unstructured":"Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment) 2009;2009:338. BMJ clinical evidence."},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry. 2003 Jan;60(1):82\u201391.","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"De Fazio P, Gaetano R, Caroleo M, Cerminara G, Maida F, Bruno A et al. Rare and very rare adverse effects of clozapine. Neuropsychiatric Disease and Treatment. 2015;11:1995\u20132003.","DOI":"10.2147\/NDT.S83989"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. 2017;40:771\u2013781. [Internet] Drug Safety. Springer International Publishing. [cited 2020 Aug 4] Available from: https:\/\/link.springer.com\/article\/10.1007\/s40264-017-0543-0.","DOI":"10.1007\/s40264-017-0543-0"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garc\u00eda-Portilla MP, Fern\u00e1ndez I et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: Results of the EIRE study. Schizophr Res. 2003 Jul;62(1\u20132):77\u201388.","DOI":"10.1016\/S0920-9964(02)00431-0"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Castle D, Inder WJ. Antipsychotic-induced hyperprolactinaemia. 2011","DOI":"10.3109\/00048674.2011.589044"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuro-Psychopharmacology Biol Psychiatry. 2007 Jan;31(1):92\u201396.","DOI":"10.1016\/j.pnpbp.2006.07.006"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. 24(7):1011\u20131018.","DOI":"10.1177\/0269881109106914"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16","DOI":"10.2174\/138161210790361461"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K et al. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results from an International, Phase III Clinical Trial. J Clin Psychopharmacol. 2015;35(4):367\u2013373.","DOI":"10.1097\/JCP.0000000000000346"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015 May;164(1\u20133):127\u2013135.","DOI":"10.1016\/j.schres.2015.01.038"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015 Dec 1;76(12):e1574\u20131582. [Internet] [cited 2020 Aug 4] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26717533\/","DOI":"10.4088\/JCP.15m09997"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003 Jun 1;61(2\u20133):123\u2013136. [Internet] [cited 2020 Aug 4] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12729864\/","DOI":"10.1016\/S0920-9964(03)00050-1"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015 Sep 1;172(9):870\u2013880. [Internet] [cited 2020 Aug 4] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25882325\/","DOI":"10.1176\/appi.ajp.2015.14101275"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"N\u00e9meth G, Laszlovszky I, Czobor P, Szalai E, Szatm\u00e1ri B, Hars\u00e1nyi J et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103\u20131113.","DOI":"10.1016\/S0140-6736(17)30060-0"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Bai Z, Wang G, Cai S, Ding X, Liu W, Huang D et al. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis. 2017;185:73\u201379. [Internet] Schizophrenia Research. Elsevier B.V. [cited 2020 Aug 4] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28108226\/","DOI":"10.1016\/j.schres.2017.01.002"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Ribeiro ELA, de Mendon\u00e7a Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. 2018;74:1215\u20131233. European Journal of Clinical Pharmacology. Springer Verlag.","DOI":"10.1007\/s00228-018-2498-1"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Greenwood J, Acharya RB, Marcellus V, Rey JA. Lumateperone: A Novel Antipsychotic for Schizophrenia. Ann Pharmacother. 2020 Jun 26; [Internet] [cited 2020 Aug 2];106002802093659. Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020936597.","DOI":"10.1177\/1060028020936597"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Kantrowitz JT. The Potential Role of Lumateperone - Something Borrowed? Something New? 2020;77:343\u2013344. [Internet] JAMA Psychiatry. American Medical Association. [cited 2020 Aug 2] Available from: https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2758020.","DOI":"10.1001\/jamapsychiatry.2019.4265"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Snyder GL, Vanover KE, Zhu H, Miller DB, O\u2019Callaghan JP, Tomesch J et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015;232(3):605\u2013621. [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC4302236\/?report=abstract.","DOI":"10.1007\/s00213-014-3704-1"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Vanover KE, Davis RE, Zhou Y, Ye W, Bra\u0161i\u0107 JR, Gapasin L et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. 2019 Feb 1;44(3):598\u2013605. Neuropsychopharmacology [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC6333832\/?report=abstract.","DOI":"10.1038\/s41386-018-0251-1"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Howes O, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. 2009 Aug 5;15(22):2550\u20132559. Curr Pharm Des [Internet] [cited 2020 Aug 2] Available from: \/pmc\/articles\/PMC3687204\/?report=abstract.","DOI":"10.2174\/138161209788957528"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Vyas P, Hwang BJ, Bra\u0161i\u0107 JR. An evaluation of lumateperone tosylate for the treatment of schizophrenia. 2020 Jan 22;21(2):139\u2013145. Expert Opin Pharmacother [Internet] [cited 2020 Aug 2] Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2019.1695778.","DOI":"10.1080\/14656566.2019.1695778"},{"key":"ref85","unstructured":"New York, NY: Intra-Cellular Therapies, Inc; 2019. Capylta (lumateperone) [package insert]"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Davis RE, Vanover KE, Zhou Y, Bra\u0161i\u0107 JR, Guevara M, Bisuna B et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl) 2015 Aug 24;232(15):2863\u20132872. [Internet] [cited 2020 Aug 2] Available from: https:\/\/link.springer.com\/article\/10.1007\/s00213-015-3922-1.","DOI":"10.1007\/s00213-015-3922-1"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Correll CU. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. 2010 Jun;25(SUPPL. 2) Eur Psychiatry [Internet] [cited 2020 Aug 2] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20620881\/","DOI":"10.1016\/S0924-9338(10)71701-6"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W et al. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. 2014 Mar 27;57(6):2670\u20132682. J Med Chem [Internet] [cited 2020 Aug 2] Available from: https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/jm401958n.","DOI":"10.1021\/jm401958n"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. 2016 Jun 2;16(6):601\u2013614. Expert Rev Neurother [Internet] [cited 2020 Aug 2] Available from: http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2016.1174577.","DOI":"10.1080\/14737175.2016.1174577"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u2013276.","DOI":"10.1093\/schbul\/13.2.261"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA et al. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. 2016 Jun 15;79(12):952\u2013961. Biol Psychiatry [Internet] [cited 2020 Aug 4] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26444072\/","DOI":"10.1016\/j.biopsych.2015.08.026"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA et al. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biol Psychiatry. 2016 Jun;79(12):952\u2013961.","DOI":"10.1016\/j.biopsych.2015.08.026"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Correll CU, Davis RE, Weingart M, Saillard J, O\u2019Gorman C, Kane JM et al. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Apr;77(4):349\u2013358.","DOI":"10.1001\/jamapsychiatry.2019.4379"},{"key":"ref94","unstructured":"24. The Clinical Development of Lumateperone (ITI-007) for the Treatment of Schizophrenia [Internet]. [cited 2020 Aug 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5475480\/"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Vanover K, Glass S, Kozauer S, Saillard J, Sanchez J, Weingart M et al. 30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study. CNS Spectr. 2019;24(1):190\u2013191.","DOI":"10.1017\/S1092852919000245"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Correll CU, Kimberly Vanover E, Durgam S, Davis R, Rowe W et al. Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia. 2020","DOI":"10.1017\/S1092852920001017"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Durgam S, Satlin A, Davis RE, Vanover KE, Mates S, Kane JM. T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS. 2020;46(Supplement_1):S310\u2013S310. Schizophr Bull.","DOI":"10.1093\/schbul\/sbaa029.765"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Kane J, Vanover K, Durgam S, Davis R, Satlin A, Rowe W et al. 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials. 2020","DOI":"10.1017\/S1092852920001005"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Kapur S, Zipursky R, Jones C, Remington G, Houle S, Roy P et al. Relationship Between Dopamine D 2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. 2000;157 Am J Psychiatry.","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Wong DF, Kuwabara H, Bra\u0161i\u0107 JR, Stock T, Maini A, Gean EG et al. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. 2013 Sep;229(2):245\u2013252. Psychopharmacology (Berl)","DOI":"10.1007\/s00213-013-3103-z"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested Minimal Effective Dose of Risperidone Based on PET-Measured D 2 and 5-HT 2A Receptor Occupancy in Schizophrenic Patients. 1999;156 Am J Psychiatry.","DOI":"10.1176\/ajp.156.6.869"},{"key":"ref102","unstructured":"Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression."},{"key":"ref103","unstructured":"Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally - Full Text View - ClinicalTrials.gov."},{"key":"ref104","unstructured":"2019 Intra-Cellular Therapies. Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology | Intra-Cellular Therapies Inc."}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:26:50Z","timestamp":1791314810000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/lumateperone-for-the-treatment-of-schizophrenia\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":104,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4372","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}